Status:

COMPLETED

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Lead Sponsor:

Janssen-Cilag International NV

Conditions:

Human Immunodeficiency Virus (HIV) Infections

Acquired Immunodeficiency Syndrome (AIDS) Virus

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare the efficacy, safety and tolerability of darunavir/ritonavir 800/100 mg monotherapy with a triple combination therapy containing darunavir/ritonavir 800/100 mg ...

Detailed Description

This is phase IIIb, randomised (study medication is assigned by chance), open-label (both the patient and the study physician will know to which treatment group the patient is assigned) trial to compa...

Eligibility Criteria

Inclusion

  • HIV-1 infection
  • receiving HAART for at least 48 weeks
  • Have at least 2 documented plasma HIV-1 RNA \<50 copies/mL, and no HIV-1 RNA \>=50 copies/mL in the 48 weeks prior to the screening
  • Be taking the same antiretroviral (ARV) combination for at least 8 weeks before screening
  • Have the preference, together with the physician, to change the current HAART regimen for reasons of simplification and/or toxicity

Exclusion

  • Has a history of virologic failure defined as 2 consecutive plasma HIV-1 RNA \>500 copies/mL while on previous or current antiretroviral therapy
  • Has a history of any primary PI mutations
  • Has clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (liver insufficiency)
  • Is diagnosed with acute viral hepatitis at screening or before Baseline 1
  • Is co-infected with hepatitis B

Key Trial Info

Start Date :

March 15 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 18 2015

Estimated Enrollment :

274 Patients enrolled

Trial Details

Trial ID

NCT01448707

Start Date

March 15 2012

End Date

March 18 2015

Last Update

November 27 2017

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

Graz, Austria

2

Vienna, Austria

3

Antwerp, Belgium

4

Brussels, Belgium